Background
==========

Mid-wall fibrosis (MWF) is a hallmark of non-ischemic cardiomyopathy (NICM) that confers increased risk for sudden cardiac death and mortality. The relationship between MWF and left ventricular (LV) remodeling is unknown.

Methods
=======

The population comprised patients with advanced systolic dysfunction (LVEF ≤ 40%) undergoing CMR (1.5T, General Electric Signa). Ischemic vs. NICM etiology was classified in accordance with established convention based on obstructive CAD on invasive angiography. Delayed enhancement CMR (IR-GRE acquired 10-30 minutes post gadolinium \[0.2 mmol/kg\]) was used to identify MWF, defined as hyperenhancement confined to the mid-myocardial or epicardial aspect of the interventricular septum. LV mass and chamber volume were quantified by planimetry of contiguous SSFP cine-CMR short axis slices, with ejection fraction (EF) calculated as the proportional difference between end-diastolic (EDV) and end-systolic (ESV) volumes.

Results
=======

523 patients (61 ± 14 yo, 72% M, 66% ischemic CM) were studied: MWF was present in 16%, and was 6-fold more common in patients with angiographically classified NICM (37% vs. 6%; p \< 0.001). Regarding LV remodeling, MWF was associated with higher EDV (134 ± 39 ml vs. 114 ± 34 ml; p \< 0.001) and LV mass (102 ± 24 vs. 96 ± 28 gm; p \< 0.001) and lower LVEF (26 ± 8% vs. 30 ± 8%; p ≤ 0.05). MWF was nearly 3-fold more common among patients in the highest tertile of EDV vs. the remainder of the population (29% vs. 10%; p \< 0.001). Multivariate regression analysis was performed to further assess markers for MWF: Restricted to imaging indices, results (Table [1](#T1){ref-type="table"}A) demonstrated EF and EDV to be independently associated with MWF (OR = 1.46, CI 1.03-2.10; p \< 0.05, OR = 1.13, CI 1.04-1.20; p \< 0.05, respectively) after controlling for mass (OR = 0.95, CI 0.85-1.00; p = 0.29). Regarding clinical variables, results (Table [1](#T1){ref-type="table"}B) confirmed a strong association with NICM (OR = 8.4, CI 4.78-14.72; p \< 0.001), independent of other clinical indices. A combined model incorporating both clinical and imaging variables demonstrated both NICM and LV volume to be independently associated with MWF even after controlling for EF (Table [1](#T1){ref-type="table"}C). Overall strength of the combined clinical/imaging (χ^2^= 91.2; p \< 0.001) model for MWF was higher than that of isolated clinical (χ^2^= 76.7; p \< 0.001) and imaging (χ^2^= 26.0; p \< 0.001) models.

###### 

Multivariate Regression for Prediction of LV MWF

  1A. Imaging                                (Model χ^2^= 26.0, p \< 0.001)                             
  ------------------------------------------ -------------------------------- ------------------------- ----------
  LV Ejection Fraction (per 10% decrement)   1.46                             1.03-2.10                 \< 0.05
  LV End-Diastolic Volume (per 10 ml/m2)     1.13                             1.04-1.20                 \< 0.05
  Myocardial Mass (per 10 gm/m2)             0.95                             0.85-1.00                 0.29
                                                                                                        
  **1B. Clinical**                           (Model χ^2^= 76.7, p \< 0.001)                             
                                                                                                        
  Variable                                   Odds Ratio                       95% Confidence Interval   P
  Hypertension                               0.10                             0.36 - 1.10               0.10
  Hypercholesterolemia                       0.94                             0.59 - 1.78               0.94
  Age (years)                                0.70                             0.99 - 1.00               0.70
  Non-Ischemic Etiology                      8.4                              4.78- 14.72               \< 0.001
                                                                                                        
  **1C. Integrated Clinical/Imaging**        (Model χ^2^= 91.2, p \< 0.001)                             
                                                                                                        
  Variable                                   Odds Ratio                       95% Confidence Interval   P
  LV Ejection Fraction (per 10% decrement)   1.22                             0.84- 1.78                0.29
  LV End-Diastolic Volume (10 ml/m2)         1.11                             1.03 - 1.20               \< 0.05
  Non-Ischemic Etiology                      8.22                             4.75 - 14.2               \< 0.001

Conclusions
===========

Among patients with advanced cardiomyopathy, MWF is associated with advanced LV chamber dilation independent of severity of LV dysfunction and cardiomyopathic etiology.
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